Pneumonia-targeted lopinavir/ritonavir-based treatment for patients with COVID-19: an early-period retrospective single center observational study.

Jongkyu KimJiwoong JungTae Ho KimNaree KangHanzo ChoiDong Hyun OhMi Young AhnSu Hyun KimChorom HahmYoung Kyong LeeKeunhong ParkKiho HongJae Phil Choi

Published in: BMC infectious diseases (2021)

Early, pneumonia targeted LPV/r-based antiviral therapy resulted in a significantly higher probability of negative conversion of PCR within 28 days compared to symptomatic treatment.

Keyphrases

cancer therapy
stem cells
bone marrow
mesenchymal stem cells
replacement therapy
intensive care unit
antiretroviral therapy
acute respiratory distress syndrome